Are benzodiazepines safe for long-term anxiety treatment?

Why this question matters

Benzodiazepines can reduce acute anxiety symptoms, but many clinical guidelines caution against routine long-term use because of dependence, withdrawal, cognitive impairment, falls, sedation, and other risks. Longer-term treatment decisions depend on the individual patient, diagnosis, dose, duration, co-occurring conditions, and availability of alternatives.

The claim being judged

The claim asks whether benzodiazepines are safe as a long-term treatment for anxiety. Benzodiazepines include medicines such as alprazolam, clonazepam, diazepam, lorazepam, and others. They act quickly and can be helpful for short-term relief of severe anxiety, panic symptoms, insomnia linked to anxiety, or crisis periods.

The key issue is not whether these medicines can ever be used, but whether they are generally safe and appropriate for ongoing anxiety treatment over months or years. Long-term use raises a different risk-benefit question than brief or intermittent use.

A careful assessment should distinguish between supervised prescribing and unsupervised use, stable low-dose use and escalating use, younger and older adults, and people with or without substance use disorders, respiratory disease, pregnancy, or other medications that increase sedation risk.

What the evidence shows

Most major clinical guidance treats benzodiazepines as short-term or second-line options for anxiety disorders rather than routine long-term maintenance therapy. Common first-line long-term approaches include cognitive behavioral therapy and antidepressants such as SSRIs or SNRIs, depending on the anxiety disorder and patient circumstances.

The main safety concerns with long-term benzodiazepine use include tolerance, physical dependence, withdrawal symptoms, rebound anxiety, sedation, impaired coordination, and difficulties stopping treatment. Some people experience significant withdrawal even after prescribed use, especially after higher doses or longer duration.

Long-term use is also associated with risks that are particularly important in older adults, including falls, fractures, driving impairment, delirium, and cognitive side effects. Combining benzodiazepines with alcohol, opioids, sleep medications, or other sedating drugs can increase the risk of dangerous respiratory depression and accidents.

There are situations where clinicians may continue benzodiazepines after weighing risks and benefits, such as when other treatments have not helped, symptoms are severe, or tapering would cause substantial destabilization. Even in those cases, guidance commonly emphasizes the lowest effective dose, periodic reassessment, avoidance of risky combinations, and a plan for monitoring or gradual tapering when appropriate.

Where uncertainty remains

The evidence base is complicated because patients who remain on benzodiazepines long term may differ from those who do not. Observational studies can show associations with harms, but they may not fully separate medication effects from the underlying severity of anxiety, insomnia, other illnesses, or use of additional medications.

There is also variation among benzodiazepines, doses, prescribing patterns, and patient groups. A person taking a low dose under close medical supervision may face a different risk profile than someone taking high doses, using multiple sedatives, or taking medication without consistent clinical oversight.

Some uncertainty remains about the long-term cognitive effects of benzodiazepines and about the best tapering strategies for different patients. However, the broad clinical pattern is that long-term benzodiazepine treatment for anxiety is approached cautiously rather than treated as broadly safe for routine use.

The three parts of the claim

The umbrella claim is actually several claims bundled into one. Each needs its own evaluation.

Common questions